PERSONALISING THERAPY: CLINICAL, HISTOLOGIC AND ENDOSCOPIC PREDICTORS OF ANTI-TNF OUTCOME IN CROHN’S DISEASE.

(1) Inflammatory bowel disease,St Mark's Hospital,London,United Kingdom

(2) Wolfson Endoscopy Unit,St Mark's Hospital,London,United Kingdom

(3) Department of Surgery,St Mark's Hospital,London,United Kingdom

(4) Pathology,St Mark's Hospital,London,United Kingdom



This item was part of UEG Week 2015

This item can be cited as: United European Gastroenterology Journal; 2015: 2 (Supplement 1)

You may be interested in:

An overview of early ulcerative colitis
English, Presentation, IBD, Postgraduate Teaching, 2017
Takeda -Revisiting treatment success in Crohn’s disease (Takeda Pharmaceuticals International AG)
English, Presentation, Industry Sponsored Symposia, Takeda Pharmaceuticals International AG, Industry Sponsored Symposia, 2019

Categorisation:

  • Format
    • Abstract
  • Year
    • 2015